CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 1-Year Low – Time to Sell?

CRISPR Therapeutics AG (NASDAQ:CRSP) hit a new 52-week low during trading on Monday . The stock traded as low as $36.70 and last traded at $37.04, with a volume of 992191 shares traded. The stock had previously closed at $39.69.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CRSP. Bank of America reduced their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Barclays reduced their price target on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. JMP Securities restated a “market outperform” rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a report on Friday, December 20th. Needham & Company LLC reiterated a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $78.38.

CRISPR Therapeutics Stock Performance

The firm has a market capitalization of $3.27 billion, a P/E ratio of -13.55 and a beta of 1.62. The stock has a 50-day moving average of $45.70 and a 200 day moving average of $48.37.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. The business had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same quarter last year, the business posted ($1.41) earnings per share. On average, equities analysts predict that CRISPR Therapeutics AG will post -5.13 EPS for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 30,000 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00. Following the transaction, the chief executive officer now owns 196,540 shares of the company’s stock, valued at $10,931,554.80. This represents a 13.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Capital Market Strategies LLC acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $461,000. Capital Advisors Inc. OK raised its holdings in shares of CRISPR Therapeutics by 8.1% in the 3rd quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock valued at $14,122,000 after purchasing an additional 22,583 shares during the period. Geode Capital Management LLC lifted its position in shares of CRISPR Therapeutics by 3.6% in the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after buying an additional 35,196 shares during the last quarter. Granite Bay Wealth Management LLC acquired a new stake in CRISPR Therapeutics during the 2nd quarter valued at $2,375,000. Finally, State Street Corp lifted its stake in shares of CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after buying an additional 599,304 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.